Openly accessible

Immuno-psychiatry: an agenda for clinical practice and innovative research

Leboyer, Marion, Berk, Michael, Yolken, Robert H., Tamouza, Ryad, Kupfer, David and Groc, Laurent 2016, Immuno-psychiatry: an agenda for clinical practice and innovative research, BMC medicine, vol. 14, Article Number : 173, pp. 1-8, doi: 10.1186/s12916-016-0712-5.

Attached Files
Name Description MIMEType Size Downloads
berk-immunopsychiatry-2016.pdf Published version application/pdf 983.84KB 42

Title Immuno-psychiatry: an agenda for clinical practice and innovative research
Author(s) Leboyer, Marion
Berk, MichaelORCID iD for Berk, Michael orcid.org/0000-0002-5554-6946
Yolken, Robert H.
Tamouza, Ryad
Kupfer, David
Groc, Laurent
Journal name BMC medicine
Volume number 14
Season Article Number : 173
Start page 1
End page 8
Total pages 8
Publisher BioMed Central
Place of publication London, Eng.
Publication date 2016
ISSN 1741-7015
Keyword(s) Biological pathways
Biomarkers
Immune inflammation
Personalised psychiatry
Translational research
Science & Technology
Life Sciences & Biomedicine
Medicine, General & Internal
General & Internal Medicine
AUTISM SPECTRUM DISORDERS
NMDA-RECEPTOR ENCEPHALITIS
MAJOR DEPRESSIVE DISORDER
PLACEBO-CONTROLLED TRIAL
BIPOLAR DISORDER
CHILDHOOD MALTREATMENT
ENDOGENOUS RETROVIRUS
CYTOKINE ALTERATIONS
AUTOIMMUNE-DISEASES
TOXOPLASMA-GONDII
Summary BACKGROUND: The diagnostic scheme for psychiatric disorders is currently based purely on descriptive nomenclature given that biomarkers subtypes and clearly defined causal mechanisms are lacking for the vast majority of disorders. The emerging field of "immuno-psychiatry" has the potential to widen the exploration of a mechanism-based nosology, possibly leading to the discovery of more effective personalised treatment strategies.

DISCUSSION: Disturbances in immuno-inflammatory and related systems have been implicated in the aetiology, pathophysiology, phenomenology and comorbidity of several psychiatric disorders, including major mood disorders and schizophrenia. A fundamental challenge in their clinical management is to identify bio-signatures that might indicate risk, state, trait, prognosis or theragnosis. Here, we provide the rationale for a clinical and research agenda to refine future clinical practice and conceptual views, and to delineate pathways toward innovative treatment discovery.

CONCLUSION: The development of bio-signatures will allow clinicians to tailor interventions to the abovementioned biomarker subtypes - a major translational goal for research in this field.
Language eng
DOI 10.1186/s12916-016-0712-5
Field of Research 110319 Psychiatry (incl Psychotherapy)
Socio Economic Objective 920410 Mental Health
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, The Authors
Free to Read? Yes
Use Rights Creative Commons Attribution licence
Persistent URL http://hdl.handle.net/10536/DRO/DU:30090262

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 12 times in TR Web of Science
Scopus Citation Count Cited 15 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 238 Abstract Views, 43 File Downloads  -  Detailed Statistics
Created: Fri, 16 Dec 2016, 11:16:00 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.